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Much progress has been made since the conceptualization of tumor angiogenesis—the induction of growth of new blood vessels
by tumor—as a salient feature of clinically significant primary or metastatic cancers. From a practicing histopathologist’s point
of view, we appraise the application of this concept in breast cancer with particular reference to the evaluation of proangiogenic
factors and the assessment of new microvessels in histopathological examination. Recently, much focus has also been centered on
the active roles played by tumor-associated macrophages in relation to tumor angiogenesis. We review the literature; many data
supporting this facet of tumor angiogenesis were derived from the breast cancer models. We scrutinize the large body of clinical
evidence exploring the link between the tumor-associated macrophages and breast tumor angiogenesis and discuss particularly
the methodology and limitations of incorporating such an assessment in histopathological examination.
1. Introduction
Angiogenesis, the growth and remodeling of new blood
vessels, is one of the hallmarks of cancer. Acquiring proan-
giogenic phenotype, tumor cells produce and release proan-
giogenic factors to initiate angiogenesis whereby the ensuing
tumor growth, invasion, and metastasis take place. Subject to
this angiogenic switch tenet for its progression, breast cancer
has been shown to produce a number of proangiogenic
factors. Studies have demonstrated that the evaluation of
these proangiogenic factors carries predictive and prognostic
values [1, 2]. Prognostic significance of tumor angiogenesis
has also been highlighted in clinical studies where higher
microvessel densities correlate with poorer survival outcome
[3]. Via the control of angiogenesis, another dimension in
therapeutic intervention is now unfolded.
In relation to tumor angiogenesis, recent research also fo-
cuses on the role of tumor microenvironment. Tumor-asso-
ciated macrophages, a major component in the leukocytic
infiltration in tumor, have aroused much research interest
since the propositions of their active involvement in tumor
progression [4, 5]. Best summarized as M2 phenotype,
tumor-associated macrophages show anti-inflammatory and
tumor-promoting characteristics, especially in relation to
tumor angiogenesis. Apart from the in vitro and in vivo
animal studies based on the breast cancer models, there is
accumulating evidence from the clinical studies that suggests
tumor-promoting features of tumor-associated macrophages
in breast cancer [6, 7].
In this paper, we outline the conceptual development
of breast tumor angiogenesis and evaluate the methodology
and limitations of quantifying proangiogenic factors and
microvessel density in the assessment of tumor angiogenesis
in breast cancer. We summarize the pertinent experimental
and clinical data exploring the link between the tumor-
associated macrophages and breast tumor angiogenesis,
emphasizing the methodology and limitations of histopatho-
logical assessment in this regard.
2. Breast Cancer and Tumor Angiogenesis
2.1. Tumor Angiogenesis Is One of the Hallmarks of Cancer.
Cancer development and progression is a complex multistep
process where novel capabilities, the hallmarks of cancer,
are acquired through the accumulation of multiple genetic
alternations. These hallmarks of cancer include not only the
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tumor’s cellular autonomy such as self-suﬃciency in growth
signals and limitless replicative potential but also the abilities
to interact with the surrounding stroma such as development
of sustained angiogenesis [8]. In particular, the ability to
activate angiogenesis plays a crucial role in controlling tumor
progression because tumor growth, invasion, and metastasis
are angiogenesis dependent [9].
Folkman first proposed angiogenesis dependency of
tumor growth and metastasis in 1971. He hypothesized
that tumor would remain in dormancy at a microscopic
size (1-2 millimeter) in the absence of angiogenesis [10].
This is comprehensible because a tumor, similar to its non-
neoplastic counterpart, requires adequate supply of oxygen
and nutrients and an eﬀective means to dispose its waste
products for survival and growth; these metabolic needs
can be fulfilled through tumor-induced angiogenesis [11].
In fact, all mammalian cells including the tumor cells are
restricted to within 100–200 μm of a capillary blood vessel
due to oxygen diﬀusion limit of about 100 μm [12].
In addition, angiogenesis facilitatesmetastasis. The newly
formed tumor blood vessels are structurally abnormal. For
instance, increased numbers of fenestrations, vesicles, and
vesicovacuolar channels and a lack of normal basement
membrane are common in tumor vessels [13]. These abnor-
mal blood vessels are consequently more permeative and
would constitute the easier entry point for tumor cells to
enter into the circulation and hence distant micrometastases
[14]. The ensuing micrometastases at ectopic places would
remain dormant unless secondary angiogenesis occurs and
paves the way for the establishment of a clinically evident
disease [15].
Angiogenic switch concept has been postulated to explain
the mechanism underlying tumor dependence on angio-
genesis to escape from dormancy. Under this concept, the
balance of proangiogenic and antiangiogenic factors would
ultimately determine the activation status of the switch.
When the balance is tilted towards the angiogenic end, the
angiogenic switch is turned on; transition from the avascular
phase into the vascular phase will be triggered, permitting
exponential tumor growth and subsequent transformation
into an aggressive phenotype [16].
Factors regulating this angiogenic switch have been
extensively explored across various tumors. More than 40
endogenous proangiogenic and antiangiogenic factors are
now known [17].
2.2. Immunohistochemical Evaluation of Proangiogenic Factors
Produced by Breast Cancer Needs Validation. Subject to the
angiogenic switch tenet for its progression, angiogenesis has
been shown by studies to be initiated in the hyperplastic
state and to intensify towards the invasive carcinoma end
of spectrum in breast cancer [18–20]. Breast cancer has
been shown to express at least six diﬀerent proangiogenic
factors. These include vascular endothelial growth factor
(VEGF) and its four isoforms (121, 165, 189, and 206 amino
acids), transforming growth factor (TGF)-β1, pleiotrophin,
acidic and basic fibroblast growth factor (FGF), placen-
tal growth factor, and thymidine phosphorylase (platelet-
derived endothelial cell growth factor) [21].
Among these factors, VEGF and associated factors have
been the centre of many studies addressing the clinical
significance of proangiogenic factors in terms of predic-
tive and prognostic values. In predicting the response to
chemotherapy or tamoxifen, higher level of VEGF in tumor
by immunohistochemistry or in tumor cytosol by EIA/ELISA
method forecasted poorer response in a number of studies
[1]. In a review of breast cancer patients, an overwhelming
81% of 37 clinical studies demonstrated that the VEGF level
in tumor or serum, as determined by either immunohisto-
chemistry or ELISA method, serves as an adverse prognostic
marker for disease-free or overall survival [2].
Selected studies within the last 10 years exploring the
prognostic significance of VEGF and associated factors in
breast cancers using immunohistochemistry methodology
are highlighted in Table 1, considering immunohistochem-
istry as a part of routine histopathological examination. As
shown in Table 1, many recent studies performing immuno-
histochemistry in evaluating the expression of VEGF and
associated factors failed to demonstrate the prognostic values
of these factors in terms of disease-free survival or overall
survival [22–37]. Some studies showed that these proan-
giogenic factors act as a poor prognostic marker but lose
their significance in multivariate analysis [38–48]. A number
of limitations in the immunohistochemistry methodology
could account for these observations. Morphometric assess-
ment is inevitably subject to the individual evaluator’s sub-
jectivity. In addition, there is no validated uniform scoring
system employed in the reported studies. Primary detecting
antibodies from various sources in these studies would give
rise to variable detection sensitivity and specificity of the tar-
geted proangiogenic factors. The establishment of a validated
immunohistochemistry evaluation is therefore essential to
gain comparable data across clinical studies. In addition, this
is particularly relevant if the pathology reporting of breast
cancer is to incorporate information regarding proangio-
genic factors for therapeutic consideration in view of avail-
ability of antiangiogenic therapy in on-going clinical trials.
2.3. Methodological Inconsistency in the Assessment of Tumor
Vascularity in Breast Cancer Limits Its Clinical Prognostic
Value. Apart from the evaluation of the regulating factors
in the angiogenic switch, the quantification of angiogenesis
in breast cancer per se has its own clinical prognostic
values. In a landmark paper, Weidner et al. demonstrated
that by immunostaining the blood vessels, the number of
microvessels per 200x field in the highest neovascularization
areas (hot spots) correlated with distant metastasis in breast
cancer patients, corresponding to a 1.17-fold (95% CI =
1.02, 1.34) increase in the distant metastasis risk for every
increase in 10 microvessels [49]. Since then, microvessel
density determined by this method and its variants has
become the most popular surrogate marker in assessing
angiogenesis across various cancers [50]. In breast cancer,
highermicrovessel densities predict higher risk of subsequent
in situ cancers and invasive recurrence of previous in
situ cancers [51], poorer response to treatment [52], and
higher occurrence of micrometastases [53–55]. In a meta-
analysis of 25 independent studies, high microvessel density
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Table 1: Summary of the selected studies in the last 10 years exploring the prognostic significance of VEGF and associated factors using
immunohistochemistry in breast cancers.
Patients Assessment of VEGF expression Prognostic value of VEGF expression
98 stage II ductal breast cancers
[26]
Antibody: monoclonal anti-VEGF165
Scoring system: 0 = none, 1 = <33%, 2 = 33–66%,
3 =>66% positive tumor cells
VEGF had no prognostic significance for overall
survival or disease-free survival
48 triple negative breast cancers
not receiving systemic adjuvant
treatment from 500 primary
breast cancers using tissue
microarrays [24]
Antibody: polyclonal anti-VEGF
Scoring system: cytoplasmic staining intensity was
scored from 0 to 3
High expression had score 3
VEGF had no prognostic significance for 5-year
breast-cancer-specific survival
125 stage II node-positive
invasive ductal carcinomas, NOS
25 stage II node-positive invasive
lobular carcinomas [23]
Antibody: polyclonal anti-VEGF-C
Staining was graded as strong, medium, or
weak-to-absent expression
VEGF-C had no prognostic significance for
overall survival or disease-free survival
172 primary breast cancer [25]
Antibody: anti-VEGF-A
Scoring system: staining intensity was graded
from 0 (negative) to 3 (strong intensity)
Positive cases had score 1–3
VEGF-A had no prognostic significance for
recurrence-free survival
116 invasive ductal breast cancers
[27]
Antibody: anti-VEGF
Scoring system: positive cases had >10% positive
tumor cell staining
VEGF-A had no prognostic significance for
overall survival in multivariate analysis
52 infiltrating ductal carcinomas,
4 intraductal carcinomas, 3
mucinous adenocarcinomas,1
medullary carcinoma, 1
inflammatory breast carcinoma
[38]
Antibody: anti-VEGF-C, anti-VEGF-D
Scoring system: sum of staining intensity (0 =
negative to 3 = strong) and percentage of positive
cells (0 = 0%, 1 = 1–10%, 2 = 11–30%, 3 =
31–50%, 4 = 51–100%)
High-expression group had score 4–7
High expression of VEGF-C/D had poorer
disease-free survival and overall survival
59 invasive ductal carcinomas,
NOS 11 other types of invasive
breast cancer [39]
Antibody: polyclonal anti-VEGF-C
Scoring system: negative, 1+ (focal expression in
<5%), 2+ (focal expression in 5–20%), 3+
(diﬀuse expression in >20%)
High-expression group had score above 2+
Shorter disease-free survival and overall survival
for high expression of VEGF-C in univariate
analysis
215 high-risk primary breast
cancers with extensive axillary
involvement [28]
Antibody: monoclonal anti-VEGF
Staining intensity was graded from 0 to 3+
Positive cases are those having any tumor areas
with positive staining
VEGF had no prognostic significance for overall
survival or relapse-free survival
177 invasive breast cancers [40]
Antibody: monoclonal anti-VEGF-A,
anti-VEGF-D, polyclonal anti-VEGF-C
Scoring system: H score (multiplying percentage
of positive carcinoma cells by the staining
intensity graded 0 to 3)
High-expressing tumors had score above the
median score
(1) Shorter overall survival for high expression of
VEGF-A in univariate analysis
(2) Shorter overall survival and disease-free
interval for high expression of VEGF-C in
univariate and multivariate analyses
(3) No prognostic significance for VEGF-D
(4) Tumours with high expression of both
VEGF-A and -C had significantly shorter overall
survival
130 invasive ductal carcinomas,
30 invasive lobular carcinomas
[41]
Antibody: polyclonal anti-VEGF-B, monoclonal
anti-VEGF-A (165, 189, 206 a.a.)
Scoring system: 0 (no or weak staining in <10%),
1 (weak-to-moderate staining in 11–20%), 2
(moderate-to-strong staining 21–50%), 3 (strong
staining in >50%)
Positive cases had score above 2
(1) VEGF-A had no prognostic significance
(2) Unfavorable disease-free and overall survival
for VEGF-B-positive cases in lymph node
metastases cases
136 invasive ductal carcinomas,
31 invasive lobular carcinomas
[42]
Antibody: polyclonal anti-VEGF-C, polyclonal
anti-VEGF-D
Scoring system: positive cases had at least 10%
immunoreactive tumor cells
Poorer overall survival for VEGF-C-positive cases
VEGF-D had no prognostic significance
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Table 1: Continued.
Patients Assessment of VEGF expression Prognostic value of VEGF expression
80 invasive ductal carcinomas, 15
ductal carcinomas in situ, 5
lobular carcinomas in situ, 14
invasive lobular carcinomas, 6
medullary carcinomas, 2 tubular
carcinomas [43]
Antibody: monoclonal anti-VEGF
Scoring system: 0 = none, 1+=< 5%, 2+ =
5–50%, 3+= >50% positive tumor cells
High reactivity cases had score above median
value
Overexpression of VEGF had both unfavorable
overall survival and disease-free survival
114 breast cancers [29]
Antibody: monoclonal anti-VEGF165
Scoring system: staining intensity was graded
from 0 (no staining) to III (most intense staining)
VEGF had no prognostic significance for
disease-free survival or cancer survival
100 invasive ductal carcinomas,
NOS, 19 invasive lobular
carcinomas [30]
Antibody: polyclonal anti-VEGF-C
Staining was graded as strong, medium, or weak
expression
VEGF-C had no prognostic significance for
overall survival or disease-free survival
323 invasive breast carcinomas
[31]
Antibody: monoclonal anti-VEGF
Scoring system: sum of staining intensity (0 =
negative to 3 = strong) and percentage of positive
cells (0 = 0%, 1 = 1–25%, 2 = 26–50%, 3 = >50%)
Positive cases had score 4–6
VEGF was not associated with incidence of
relapse or death
181 invasive ductal carcinomas,
22 invasive lobular carcinoma, 8
invasive ductal and lobular
(mixed) carcinomas, 5 ductal in
situ carcinomas, 1 medullary
carcinoma [32]
Antibody: anti-VEGF-C
Scoring system: cytoplasmic staining was graded
negative (negative), 1+ (10–39%), 2+ (40–69%),
3+ (>70%)
VEGF-C had no prognostic significance for
disease-free survival
238 invasive breast cancers not
receiving tamoxifen from 500
primary breast cancers using
tissue microarrays [22]
Antibody: polyclonal anti-VEGF
Scoring system: cytoplasmic staining intensity was
scored from 0 to 3
High staining intensity group had score 3
VEGF had no prognostic significance for
relapse-free survival
87 primary breast cancers [33]
Antibody: polyclonal anti-VEGF-C
Scoring system: 0 (no staining or cytoplasmic
staining in <10%), 1+ (faint cytoplasmic staining
in >10%), 2+ (weak-to-moderate complete
cytoplasmic staining in >10%), 3+ (strong
complete cytoplasmic staining in >10%)
Positive cases had score 2+ or 3+
VEGF-C had no prognostic significance for
disease-free survival or overall survival
224 invasive breast cancers using
tissue microarrays [44]
Antibody: polyclonal anti-VEGF
Scoring system: staining intensity was graded
from 0 (negative) to 3 (intense intensity), and the
percentage of positive cells was recorded (0 = 0%,
1 = <1%, 2 = 1–10%, 3 = 10–50%, 4 = 50–90%, 5
= >90%)
Positive cases are those having any positive
staining
VEGF-A-positive cases had favorable disease-free
survival at 10-year followup in multivariate
analysis
207 invasive breast carcinomas
[34]
Antibody: polyclonal anti-VEGF-D
Scoring system: 0 = negative, 1 = weak focal
staining, 2 strong focal/widespread moderate
staining, 3 = strong widespread staining
Positive cases had score 2 or 3
VEGF-D had no prognostic significance for
overall survival or relapse-free survival
96 invasive ductal carcinomas, 9
other invasive carcinomas [45]
Antibody: monoclonal anti-VEGF-D
Scoring system: positive cases had more than 10%
tumor cells with cytoplasmic staining
(1) Positive VEGF-D cases had poorer disease-free
survival in univariate and multivariate analyses
(2) Positive VEGF-D cases had poorer overall
survival in univariate analysis
228 invasive unilateral breast
carcinomas [35]
Antibody: monoclonal anti-VEGF (isoforms 121,
165 and 189)
Scoring system: positive cases had more than 1%
immunoreactive tumor cells
VEGF had no prognostic significance for overall
survival or relapse-free survival
114 invasive ductal carcinomas, 9
other invasive carcinomas [46]
Antibody: polyclonal anti-VEGF-C
Scoring system: positive cases had more than 10%
immunoreactive tumor cells
Positive VEGF-C cases had poorer disease-free
survival and overall survival in univariate analysis
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Table 1: Continued.
Patients Assessment of VEGF expression Prognostic value of VEGF expression
99 invasive ductal carcinomas,
NOS [36]
Antibody: anti-VEGF
Scoring system: positive cases had more than 10%
tumor cells with membrane or cytoplasmic
staining
VEGF had no prognostic significance for overall
survival or relapse-free state
107 primary invasive breast
carcinomas [47]
Antibody: anti-VEGF-A, anti-VEGF-C,
anti-VEGF-D
Scoring system: computer-assisted image analysis
based on the percentage of immunostained
surfaces and mean optical density
High-expression group had value equal to or
higher than median
(1) High-VEGF-A-expression cases had worser
disease-free survival
(2) VEGF-C or VEGF-D had no prognostic
significance
(3) Cases with both low VEGF-A and VEGF-C
expression had better disease-free survival
242 node-negative breast cancer
[37]
Antibody: polyclonal anti-VEGF isoforms 121,
165, 189, and 206
Scoring system: high-expression cases had >40%
immunopositive tumor cells
VEGF had no prognostic significance for
disease-free survival or overall survival
94 invasive breast cancer, 4
noninvasive cancer [48]
Antibody: polyclonal anti-VEGF-C
Scoring system: positive cases had over 10%
tumor cells stained positively
VEGF-C-positive group had poorer disease-free
survival
significantly predicted poor relapse-free survival and overall
survival (both RR = 1.54, 95% CI = 1.29, 1.84) [3].
However, scrutinizing each of the studies included in
the above-mentioned meta-analysis, variations in results
regarding prognostic value of microvessel density in breast
cancer patients’ survival are apparent [3]. The choice of
antibodies to highlight the blood vessels in various studies
could be a contributing factor because each antibody has its
own specificity and sensitivity against the endothelial cells
of the blood vessels. Among the commonly used antibodies
are antibodies against factor-VIII-related antigen, CD31, and
CD34. Anti-CD34 is now considered the optimal marker
for its higher sensitivity without high failure rate in antigen
retrieval for invasive breast carcinoma studies [3, 56–58].
Another factor to consider in assessing microvessel de-
nsity is the variations from the original method designed by
Weidner et al. These include variables such as the number
of hot spots counted, the areas and fields of magnification
(magnification of a field area of 200x or 400x), the subjectiv-
ity in identification of what constitutes a stained blood vessel,
and also the descriptive statistics in reporting the number
of microvessel density (the mean or the highest value). To
overcome the subjectivity of observers, a 25-point Chalkley
microscope eyepiece graticule has been introduced. The
graticule is orientated in such a way that it gives the maxi-
mum number of graticule points overlapping the highlighted
vessels. This method measures relative area and has strong
association with vessel area and number [3, 57–59]. Both
the conventional optical assessment method and the Chalk-
ley method have been used in studies that demonstrated
increased microvessel density as a poor prognostic factor
[3, 60, 61]. Controversies over the best methodology remain
despite a proposed consensus of using Chalkley method in
angiogenesis quantification in solid human tumors [58].
2.4. Antiangiogenic Therapy Gives Promising Results in Pre-
clinical Studies but Not in Clinical Trials of Metastatic Breast
Cancer. Given the pivotal roles of proangiogenic factors in
tumor angiogenesis, these factors serve as reasonable phar-
macological targets for inhibition of tumor angiogenesis.
Among these factors, blockage of the VEGF pathways was the
focus of many preclinical studies because VEGF is the most
potent proangiogenic factor [62].
A number of experimental xenograft models using diﬀer-
ent tumor cell types including breast carcinomas showed that
anti-VEGF therapy resulted in 25% to 95% of tumor growth
inhibition in a dose-dependant manner. Functionally, tumor
microvascular permeability was also reduced [63]. Upon
antiangiogenic drug treatment, tumor vessels remodel and
transiently resemble the normal vessels. During this normal-
ization window, the normalized tumor vessels are believed
to be more eﬃcient in delivering the nutrients as well as
cytotoxic drugs and oxygen, potentiating the eﬀects of the
combination of cytotoxic and antiangiogenic therapies tar-
geting the tumor cells and endothelial cells, respectively [64,
65]. This tumor vasculature normalization model provides a
rationale for the observed better eﬀects of combined cyto-
toxic and anti-VEGF therapy as compared to single-agent
treatment in preclinical studies [63]. Although this tumor
vasculature normalization model is conceptually appealing,
histologic examination of vasculature normalization in clin-
ical setting to identify the optimized normalization window
is limited in several aspects such as representative multiple
small biopsies that would be hardly obtained for the global
assessment of the solid tumor [64, 65].
Results from the preclinical studies pave the way for the
use of anti-VEGF therapy in clinical trials. However, the
results from the recent phase III clinical trials in breast cancer
treatment using bevacizumab, a humanized monoclonal
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antibody against VEGF, are not as promising as in animal
studies. A meta-analysis including five reported clinical trials
involving metastatic breast cancer patients showed that the
combined bevacizumab and chemotherapy arm had better
objective response (RR = 1.26, 95% CI = 1.17, 1.37) and
progression-free survival (HR = 0.70, 95% CI = 0.60, 0.82)
as compared to the chemotherapy-alone arm. However,
no significant advantage was seen with the addition of
bevacizumab as compared to the chemotherapy-alone arm
for overall survival (HR = 0.90, 95% CI = 0.80, 1.03)
[66].
Two trials have published results and one has a report
published recently for further inspection of the study
design [83–85]. Although bevacizumab specifically blocks
the VEGF-mediated pathways, all of these trials used beva-
cizumab as a general therapy given on a population basis
without considering the specific molecular phenotype of
the breast cancer. VEGF expression profile of the cancers
was not investigated in the enrolled patients and the best
methodology of evaluation has not yet been validated.
Redundancy of other proangiogenic factors might also play
important roles in advanced breast cancer. Consideration in
these factors is needed to better stratify the patients who will
most likely benefit from the VEGF-targeted therapy.
3. Roles of Tumor-AssociatedMacrophages
in Breast Cancer
3.1. Macrophages Are Recruited into the Tumor. Infiltration
of leukocytes in tumors was first recognized by Virchow
in 1863 prompting him to postulate the link between the
origin of cancer and inflammation [4]. This link, arbitrarily
termed the extrinsic pathway, increases the risk of cancer
development, exemplified by inflammatory conditions asso-
ciated with malignancy such as ulcerative colitis linked to the
development of colon cancer. In contrast, it is now evident
that the intrinsic pathway, genetic alterations causing can-
cer without casual relationship to inflammatory processes,
also leads to a protumor inflammatory microenvironment
[86].
Among the heterogeneous populations of the leukocytic
infiltrates, it has now been established that macrophages
constitute the major proportion; for instance, up to
50% of cell mass in breast carcinoma is composed of
macrophages [87]. These macrophages are called tumor-
associated macrophages. They are mostly derived from the
peripheral blood monocytes and recruited into the tumor
by a wide range of chemokines and growth factors released
by the tumor cells. Among these, CC chemokines, partic-
ularly CCL2 (formally monocyte chemoattractant protein-
1 or MCP-1) and CCL5, and growth factors such as
colony-stimulating factor-1 (CSF-1) and vascular endothelial
growth factor (VEGF) are strongly implicated inmacrophage
recruitment in various tumors including breast cancer
[88].
3.2. Tumor-Associated Macrophages Are Polarized into M2
Phenotype in Tumor Microenvironment. The interaction
between the tumor cells and the recruited tumor-associated
macrophages has aroused much research study interest. The
classical view of tumor-associated macrophages displaying
antitumor response to destroy the tumor cells, similar to
their pathophysiological response to microbial invasion, has
however been confronted by a large number of studies that
contradictorily showed their opposite protumor response.
This paradoxical function of tumor-associated macrophages
in relation to tumor is explained by the macrophage
balance hypothesis where the outcomes of the tumor-
associated macrophages depend on the polarization between
two extremes of a continuum: M1 as proinflammatory
and microbicidal/tumoricidal phenotype in contrast to
M2 as anti-inflammatory and tumor-promoting phenotype
[5].
Clinical studies across various human tumors exploring
correlation between tumor-associated macrophage density
and prognosis have shown constant strong inverse relation-
ship in carcinomas of breast and cervix but a minority
of conflicting results in prostate, stomach, and lung can-
cers [89]. These results suggest the importance of tumor
microenvironment in tilting the macrophage balance and
support largely the polarization of macrophage into protu-
mor M2 phenotype by most tumors, including the breast
carcinomas.
3.3. Tumor-Associated Macrophages Enhance Tumor Progres-
sion in Breast Cancer. In vitro and in vivo animal studies,
especially the animal model of mammary tumor, have shed
much light on the roles of tumor-associated macrophages
in tumor progression. For instance, when a null mutation
colony stimulating factor-1 gene was crossed into transgenic
mice susceptible to mammary cancer due to the expression
of the polyoma middle T antigen oncogene (PyMT mice),
depletion of macrophages resulted in delayed tumor pro-
gression and tumormetastasis. In contrast, overexpression of
CSF-1 gene resulted in increased macrophage infiltrates and
in turn accelerated tumor progression and tumor metastasis
[90].
Restricting the data pertinent to human breast cancer, the
increased tumor-associated macrophages number correlates
with high proliferative activity of the tumor cells as indicated
by highermitotic grade and Ki-67 labelling [6, 69, 76, 77, 81].
This association could be explained by the direct mitogenic
stimulation of tumor cells by tumor-associated macrophages
or indirect eﬀect via stimulation of tumor angiogenesis by
tumor-associated macrophages as discussed below. For the
former possibility, tumor-associated macrophages indeed
express and release a wide range of growth factors such
as epidermal growth factor, basic fibroblast growth factor-2
(FGF-2), transforming growth factor-β, VEGF, and platelet-
derived growth factor (PDGF) [91]. In particular, it has been
shown that tumor-associated macrophages secrete epidermal
growth factor, but the normal or malignant breast cancer
cells do not [92]. Many breast cancers express epidermal
growth factor receptor [93], which upon activation by this
ligand leads to tumor survival and proliferation [94].
Furthermore, a paracrine loop between breast cancer
cells and tumor-associated macrophages could promote the
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invasion of breast carcinoma via reciprocal stimulation
because CSF-1 secreted by breast cancer cells recruits
macrophages, and epidermal growth factor derived from
the recruited macrophages promotes tumor cell motility
[95]. In addition, tumor-associated macrophages produce
enzymes and inhibitors, which regulate the digestion of
the extracellular matrix such as matrix metalloproteinases
(MMPs) [96] and urokinase-type plasminogen activator
(uPA) [97]. Accordingly, degradation of the extracellular
matrix by these macrophage proteases would facilitate the
invasion of tumor cells into the stroma and hence metastasis
[89, 98]. This constitutes one of the mechanisms explaining
the association of poor prognosis in breast cancer with higher
macrophage density in clinical studies [7, 71, 77, 79].
3.4. Tumor-Associated Macrophages Enhance Tumor Angio-
genesis in Breast Cancer. As discussed above, tumor angio-
genesis is crucial for tumor progression. Tumor angiogenesis
was initially thought to be induced only by tumor cells them-
selves; however, tumor-associated macrophages are indeed a
major player in the regulation of tumor angiogenesis [99]. It
is now evident that tumor-associated macrophages recruited
into the tumor microenvironment are producers of a wide
range of proangiogenic factors, including IL-1, VEGF, IL-8,
bFGF, and TNF-α [100].
The process of activation and transformation of the
tumor-associated macrophages into this proangiogenic phe-
notype is dependant on several tumor microenvironmental
stress factors such as low oxygen, low pH, and high lactate
concentration [101]. Tumor hypoxia appears to be the major
regulating factor. One study has shown that the median
pO2 value in breast cancer was 30mmHg compared to
65mmHg in normal tissue and could be as low as between
zero and 2.5mmHg [102]. Macrophages are attracted to
these hypoxic areas [70, 73], and via the hypoxia-induced
pathway, large numbers of genes encoding the proangiogenic
factors are dramatically upregulated in the tumor-associated
macrophages [103].
The first clinical study correlating tumor-associated
macrophages and angiogenesis also came from a study
on breast cancer. Significant correlation between the two
was shown in addition to the prognostic value of tumor-
associated macrophages, implying the crucial role of angio-
genesis driven by tumor-associated macrophages in breast
cancer progression [7]. Later clinical studies also produced
similar findings [76, 77, 79, 81]. In vivo animal study employ-
ing PyMT mice showed that the inhibition of macrophage
maturation and infiltration into tumors delayed angiogenesis
and tumor progression, providing evidence of causal role of
tumor-associated macrophages in tumor angiogenesis [104].
3.5. Assessment of Tumor-Associated Macrophages in Breast
Cancer by Immunohistochemistry Varies in Clinical Studies.
Major findings in recent clinical studies exploring the
link between the tumor-associated macrophages and other
clinicopathological parameters in invasive breast carcinomas
using immunohistochemistry are summarized in Table 2.
These studies are generally agreeable in terms of association
between the density of macrophages and clinicopatholog-
ical parameters related to tumor progression. Besides, the
significant association between density of macrophages and
microvessel density implies the role of tumor-associated
macrophages in tumor angiogenesis.
As shown in Table 2, in all but two studies, the anti-
body against CD68 was used to highlight the presence of
macrophages. However, there is variation in the methods
used to assess tumor-associated macrophages in these stud-
ies. Some studies used semiquantitative methods [68, 76,
78, 79] and others used quantitative methods with variation
in selection of fields and count [6, 7, 70–75, 77, 80–82].
These variations in assessment method would give rise
to minor discrepancies among the studies. In particular,
no much attention was given to the location of tumor-
associated macrophages in relation to breast carcinomas. It is
known that the tumor-associated macrophages are attracted
to hypoxic tumor areas, and angiogenesis is likely to be
induced at these hypoxic areas. Most studies used the “hot
spot” method to identify the areas of the highest number of
tumor-associated macrophages [7, 70–75, 77, 80–82]. These
studies most probably have evaluated the tumor-associated
macrophages at tumor margin where angiogenesis occurs,
as opposed to tumor-associated macrophages within the
tumor nest where information regarding their role is still
lacking [105]. Evaluation by this “hot spot” methodology
could also alleviate the concern about the confounding
macrophages induced by biopsies prior to surgical resection
of the tumor, as it is unlikely that a biopsy tract would induce
accumulation of macrophages only at the tumor margin.
Given the many positive findings regarding the associa-
tion of macrophages and breast tumor progression, a stan-
dardized evaluation method for assessing tumor-associated
macrophages is therefore necessary to harmonize future
research. A consensus of using “hot spot” method with
particular reference to tumor-associated macrophages in
tumor stroma would probably constitute such a template for
examination.
3.6. Targeting Tumor-Associated Macrophages in Breast Cancer
Represents an Attractive Approach. A plethora of growth
factors, cytokines, and chemokines are employed in the
process of recruitment, survival, activation and polarization,
proangiogenic activity, and matrix remodeling of tumor-
associated macrophages. These factors represent reasonable
therapeutic targets [106]. For instance, in an experimental
breast cancer model, antagonizing the chemokine CCL5
receptors expressed on the macrophages reduced the number
of tumor-associated macrophages and slowed the tumor
growth [107]. Using the anti-VEGF antibody to treat
breast cancer xenografts, in addition to the inhibition of
angiogenesis, infiltration of tumor-associated macrophages
was also reduced. In these studies, tumor growth and
distant metastases were inhibited [108, 109]. Although the
contribution of reduction of tumor-associated macrophages
to the observed results in these experimental studies has yet
to be determined, pathological correlation in this aspect in
the clinical trials employing anti-VEGF therapy would be of
great interest.
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Table 2: Summary of clinical studies exploring the link between tumor-associated macrophages and other clinicopathological parameters
in invasive breast carcinomas.
Tumor type
Means of tumor-associated macrophages
assessment
Findings
101 invasive breast carcinomas
[7]
Macrophage marker: CD68
Macrophage index was determined by 25-point
Chalkey graticule as the mean of three “hot spot”
counts under 250x field
(1) High macrophage index correlated with high
vascular grade
(2) High macrophage index in poorly
vascularized areas
(3) High macrophage index predicted reduced
relapse-free and overall survival
75 invasive breast carcinomas
with lymphoplasmacytic
infiltrates [67]
Macrophage marker: CD11c
Macrophage was counted as percentage of total
leukocyte infiltrate identified by CD45
(1) Macrophage predominance in leukocyte
infiltrate correlated with high grade and c-erbB-2
expression
75 invasive breast carcinomas (50
ductal, 9 lobular, 5 mixed, 5
tubular/cribriform, 1 mucinous)
[68]
Inflammation was classified as diﬀuse,
perivascular, and perilobular on H&E and also
using markers. Intensity was qualitatively graded
as from 0 (absent) to 3 (marked)
Macrophage marker: CD68
(1) In diﬀuse inflammation pattern, macrophage
intensity predominated other cell types and was
associated with high-grade, large tumor size,
tumor necrosis, and c-erbB-2 expression
(2) Intensity of diﬀuse inflammation but not
macrophage correlated with vascularity
120 invasive breast carcinomas
(60% ductal, 20% lobular, 20%
others) [6]
Macrophage marker: CD68 (KP-1 antibody)
Macrophages were counted in 40 hpf (20 hpf
tumor cell zones and 20 hpf stromal zones) and
graded from weak (<300) to intense (>500)
(1) Intensity of macrophage was higher in
node-negative tumors
(2) Intratumoral macrophage infiltration
correlated with high tumor grade, absence of ER,
and high mitotic grade
57 invasive breast carcinomas
NOS (abstract) [69]
Macrophage marker: CD68
(1) Tumor-associated macrophages correlated
with mitotic activity index
109 invasive breast carcinomas
(ductal 88, lobular 8, others 13)
[70]
Macrophage marker: CD68
Macrophage index was determined by 25-point
Chalkey graticule as the mean of three “hot spot”
counts under 250x field
(1) Higher macrophage index associated with
necrosis
26 invasive ductal carcinomas
(13 cases <5 years, 13 cases >5
years’ survival) [71]
Macrophage marker: CD68
Hot spots were identified under 100x, field and
macrophages were counted in 5 hpf under 400x
field
(1) Higher macrophage count in poor prognosis
group
151 invasive ductal carcinomas
[72]
Macrophage marker: CD68
Macrophages were counted in 5 hot spots, and the
mean of the highest three was determined (per
mm2)
(1) High macrophage count correlated with high
levels of macrophage chemoattractant protein-1
and thymidine phosphorylase in breast cancer by
ELISA
(2) High level of macrophage chemoattractant
protein-1 had worsened relapse-free survival
96 invasive breast carcinomas (78
ductal, 7 lobular, 11 others) [73]
Macrophage marker: CD68
Macrophage index was determined by 25-point
Chalkey graticule as the mean of three “hot spot”
counts under 250x field
(1) Macrophage index correlated with high VEGF
and EGFR expression
(2) In EGFR-negative cases, high VEGF correlated
with increased macrophage index, high grade,
presence of necrosis, and increased tumor p53
expression
(3) No significant prognostic value of VEGF
24 invasive breast carcinomas (12
ductal, 12 lobular) [74]
Macrophage marker: CD68
Macrophage index was determined by 25-point
Chalkey graticule or by absolute count as the
mean of five VEGF positive areas under 200x
field. In VEGF-negative areas, 5 most or least
vascularized areas were chosen
(1) Macrophage count was higher in less
vascularized areas
230 invasive ductal carcinomas
[75]
Macrophage marker: CD68 macrophages were
counted in 5 hot spots, and the mean of the
highest three was determined (per mm2).
Graded from 0 (<50/mm2) to 2 (>100mm2)
(1) High macrophage count showed a tendency of
correlation with high level of tumoral
macrophage chemoattractant protein-1 by
immunohistochemistry (P = .089).
(2) High level of tumoral macrophage
chemoattractant protein-1 showed a tendency of
correlation with high microvessel density grade
(P = .087)
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Table 2: Continued.
Tumor type
Means of tumor-associated macrophages
assessment
Findings
97 invasive ductal carcinomas
[76]
Macrophage marker: CD68
Macrophages were semiqualitatively graded as 1 =
no macrophages, 2 = small foci of macrophages, 3
= large foci of macrophages 4 = diﬀuse
macrophages infiltration in tumor stroma
(1) Higher macrophage grade associated with
higher VEGF expression, higher microvessel
density, and higher mitotic activity index
249 invasive ductal carcinomas
(abstract) [77]
Macrophage density was assessed as average
density of three hot spots at a magnification of
400x
(1) Macrophage density significantly correlated
with both the VEGF expression and MVD
(2) Macrophage density was associated with the
nuclear grade, estrogen receptor status, and
MIB-1 count
(3) Patients with a high macrophage density had a
significantly worse disease-free survival prognosis
than those with a low density
97 breast carcinomas [78]
Macrophage marker: CD68
Macrophages were semiqualitatively graded as 1 =
no macrophages, 2 = small and large foci of
macrophages, 3 = diﬀuse macrophages infiltration
in tumor stroma
(1) Macrophage grade was not correlated with
tumor chemoattractant protein-1
78 invasive breast carcinomas (48
ductal, 30 lobular) [79]
Macrophage marker: HAM56 antibody
Macrophages were semiqualitatively graded as 1 =
no macrophages, 2 = small foci of macrophages, 3
= large foci of macrophages, 4 = diﬀuse
macrophages infiltration in tumor stroma
(1) Higher macrophages in invasive ductal
carcinomas compared to invasive lobular
carcinomas
(2) In invasive ductal carcinomas, macrophage
grade correlated with tumor size, lymph node
metastasis, stage, microvessel density, VEGF, and
tumor grade
(3) In invasive ductal carcinomas, macrophage
grade and clinical stage were predictive in
disease-free survival rate
133 invasive breast carcinomas
(94 ductal, 28 lobular, 8
mucinous, 3 papillary) [80]
Macrophage marker: CD68
Macrophages were counted in 5 consecutive 400x
fields in areas identified as “hot spots” under 100x
(1) Higher macrophage count associated with
high tumor grade, p53 expression, absence of ER,
high VEGF expression in macrophage, and
postsurgical serum VEGF level
168 invasive primary breast
cancer (142 ductal, 20 lobular, 6
others) [81]
Macrophage marker: CD68
Macrophages were counted using point counting
method (expressed as percentage of volume
occupied by a component out of total volume)
using a 100-point ocular grid counting at 400x
field over 30 fields and were grouped tertiles
(1) High tertile percentage of macrophage
correlated with high tumor grade, high Ki-67
labelling, absence of hormonal receptors, high
microvessel density, high CD4 and CD8 count
128 invasive ductal carcinomas
[82]
Macrophage marker: CD68
Macrophages were counted as mean of the 3
densest areas at 200x field (per mm2) following a
brief scan at low power and separated into <320
or >320/mm2 groups
(1) Macrophage count correlated with stromal
chemoattractant protein-1
(2) Stromal chemoattractant protein-1 correlated
with lymphatic invasion and predicted worsened
relapse-free survival
4. Conclusion
In conclusion, the salient points regarding trilateral rela-
tionship among breast cancer cells, tumor-associated macro-
phages, and tumor angiogenesis are
(1) breast cancer progression is dependent on tumor
angiogenesis,
(2) breast cancer cells are able to regulate tumor angio-
genesis via production of proangiogenic factors,
(3) tumor-associated macrophages have emerged as a
major player in regulating breast cancer progression,
(4) as a major regulatory mechanism in tumor progres-
sion, tumor-associated macrophages enhance breast
tumor angiogenesis,
(5) breast cancer progression involves reciprocal inter-
actions between breast cancer cells and tumor-
associated macrophages.
At the tissue level, the assessment of the relationship
between these three compartments is feasible by histopatho-
logical examination coupled with immunohistochemistry.
Despite its limitations, microvessel density has been widely
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used as a surrogate marker for tumor angiogenesis. Estab-
lishment of a validated immunohistochemical evaluation of
proangiogenic factors produced by breast cancer is essential.
Information regarding expression profile of proangiogenic
factors might help to stratify patients receiving antiangio-
genic therapy. Tumor-associated macrophage density can
be graded in similar manner as microvessel density evalu-
ation. Assessment in this regard would possibly constitute
another important item in histopathological examination for
prognostication, considering therapeutic advances targeting
tumor-associated macrophages.
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